FOLFOXIRI-based HAIC+Fuquinitinib
Approval No. 380, 2023
Phase 2 small_molecule completed
Quick answer
FOLFOXIRI-based HAIC+Fuquinitinib for Colorectal Neoplasms is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Colorectal Neoplasms
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed